# SpyBiotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spybiotech

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.spybiotech.com
- Total disclosed funding: $38M
- Latest round: Series A (Feb 4, 2021)
- Investors on record: 5

## About

SpyBiotech Limited, based in the UK, specializes in biotechnology, focusing on developing innovative vaccines utilizing its proprietary protein superglue technology. The company aims to address significant health challenges through effective vaccine solutions.SpyBiotech Limited, founded in 2017 in Oxford, UK, concentrates on innovative vaccine development. The company has completed 3 deals, with the latest being a Series A round in February 2021, raising GBP 23.80 million led by Braavos Ventures. The CEO is Mark Leuchtenberger, and the company is founded by Simon Draper. SpyBiotech has not undergone any noted pivots or structural changes since its inception.SpyBiotech is focused on developing innovative vaccines using its proprietary protein superglue technology, SpyTag/SpyCatcher. This technology facilitates the creation of safe vaccines aimed at preventing infectious diseases and treating cancer. The company's primary product pipeline includes a vaccine targeting cytomegalovirus (CMV). Its products are expected to serve a variety of markets, including healthcare providers and pharmaceutical partners across North America, Europe, and select Asian markets.SpyBiotech’s revenue model is based on collaborations with healthcare organizations and pharmaceutical companies engaged in vaccine development. In the most recent year, 2019, the company reported revenue of GBP 55,085.60. SpyBiotech focuses on strategic partnerships to deliver its vaccine products, reflecting a commitment to collaborative biotechnology development.In February 2021, SpyBiotech Limited raised GBP 23.80 million to advance clinical development of its novel vaccine technology platform. The funding will support the initiation of a Phase I clinical study of its lead candidate, targeting human cytomegalovirus (HCMV), planned for early 2022. The company aims to expand its market presence in Europe and North America as it develops new products.

## Funding rounds

- Series A, Feb 4, 2021, $33M — Future Fund, GV, Oxford Sciences Enterprises, Braavos Ventures, Oxford Investment Consultants
- Seed, Mar 10, 2017, $4.9M — GV, Oxford Sciences Enterprises

## Investors

- GV (https://capitalatlas.ai/funds/gv) — Seed, Series A
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed, Series A
- Future Fund — Series A
- Braavos Ventures (https://capitalatlas.ai/funds/braavos-ventures) — Series A
- Oxford Investment Consultants — Series A